Bioavailability Enhancement: When to Use Hot-Melt Extrusion versus Spray Drying - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bioavailability Enhancement: When to Use Hot-Melt Extrusion versus Spray Drying
Enhancing bioavailability can be achieved through hot-melt extrusion or spray drying. The drug product's API properties and stage of development are important factors to consider when deciding which technique to use.


Pharmaceutical Technology
Volume 36, Issue 8, pp. 44-45

Recent advances

PharmTech: On an industry level, can you highlight recent advances in HME with respect to improvements in the manufacturing process and its application to different types of APIs?

Bend Research: HME is a technology that has been widely used in pharmaceutical and nonpharmaceutical industries for decades. Recent advances in HME include efforts to reduce processing temperatures by including plasticizers and reduce the residence time of the compound and polymer during processing. Numerous research groups are looking at nonvolatile plasticizers, such as vitamin E or triethyl citrate, to reduce processing temperatures. Others have reported the use of volatile excipients, such as supercritical carbon dioxide, to avoid decreases in the final dispersion's glass-transition temperature that occur with traditional plasticizers.

There have also been recent reports of the use of equipment that has significantly reduced residence time. Professor McGinity's research group at the University of Texas has developed a process called Kinetisol to make amorphous dispersions. It is based on equipment that was developed to recycle plastics, which can reduce the residence time of the API and polymer at processing temperatures from minutes to tens of seconds.

PharmTech: Can you highlight recent industry advances in spray drying with respect to improvements in the manufacturing process and its application to different types of APIs?

Bend Research: Although spray drying is a well-established process, innovations in formulation approaches and process equipment are occurring. In formulation, there is an increasing need for a third component in the dispersions to help deliver challenging compounds aimed at novel biological targets. Often, a surfactant is added to help increase the dissolution rate or dispersion-particle wetting or to provide an alternate micelle source to enhance drug solubility in vivo.

Equipment advances include novel spray-dryer and cyclone designs to collect the dispersion particles more efficiently. This is especially significant for particle-engineering applications such as inhalation, which requires the manufacture and collection of particles with a narrow particle-size distribution for delivery to the lung.

As part of the effort to formulate compounds with low solubility in organic solvents, Bend Research has developed a "hot process," which allows a drug suspension to be heated to high temperatures—often well above the ambient-pressure boiling point of the solvent—in a heat exchanger to dissolve the drug immediately before it is introduced into the spray dryer. This decreases solvent use and can result in a more scalable process.

PharmTech: One specific technology of Bend Research is the spray-dried nanoadsorbate technology. Can you explain this technology and how it differs from conventional spray drying?

Bend Research: Two physical situations are dose-limiting when formulating amorphous dispersions: low dissolution rates for compounds that are highly lipophilic and recrystallization for compounds that have high melting temperatures. To formulate highly lipophilic compounds, we have developed the spray-dried nanoadsorbate technology as an extension of spray-dried dispersions. This technology is based on spray drying an amorphous dispersion onto a high-surface-area inorganic support such as Cab-O-Sil (fumed silica). The increased surface area promotes faster dissolution of the dispersion and is particularly well suited for highly lipophilic compounds (e.g., compounds that have LogP values greater than 6 to 7). Similarly, to formulate compounds with high melting temperatures, we have developed a technology that is based on intentionally recrystallizing the compounds in the dispersion polymer in nanometer-sized domains. This formulation type also is a high-energy form of the API that contains a concentration-enhancing polymer.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here